Alan Shaw is a prominent figure in biotechnology who has made significant contributions as the CEO of Codexis, Inc. from 2011 to 2017. With a Ph.D. in Chemistry from Stanford University, his strong science background has fueled his career in...

Alan Shaw is a prominent figure in biotechnology who has made significant contributions as the CEO of Codexis, Inc. from 2011 to 2017. With a Ph.D. in Chemistry from Stanford University, his strong science background has fueled his career in developing innovative biotechnologies. During his tenure at Codexis, the company focused on advancing biotherapeutics, achieving notable financial success, and hitting a corporate performance factor of over 115% in 2010. In 2017, his total compensation reached approximately $3.37 million, reflecting his performance-driven leadership style, which aligned executive compensation with company performance and shareholder interests. Interestingly, Alan has been actively involved in stock trading and his holdings fluctuated significantly, peaking at nearly $6.60 million in early 2021. His dynamic leadership has not only shaped Codexis’s strategy and growth but also highlighted the crucial intersection of science and business in today's fast-evolving market. Beyond his corporate roles, Alan Shaw has left a mark through his clear understanding of the biotech landscape and the importance of measurable performance metrics.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Codexis CEOs

C

Alan Shaw

Ex-CEO of Codexis

Education

Ph.D. in Chemistry from Stanford University.

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1961 - 64 years ago

CEO of Codexis for

6 years 8 months (Mar 2011 - Nov 2017)

Previous Experience

Various roles in management and executive positions in biotechnology companies.

Rivals

Competitors/colleagues of Alan Shaw

Holdings

See how much did Alan Shaw make over time.

Alan Shaw’s insider trading and holdings in Codexis have seen notable ups and downs. His stock holdings peaked at about $6.60 million in January 2021, showcasing significant confidence in Codexis's future. However, after reaching this high point, the value of...

Alan Shaw’s insider trading and holdings in Codexis have seen notable ups and downs. His stock holdings peaked at about $6.60 million in January 2021, showcasing significant confidence in Codexis's future. However, after reaching this high point, the value of his holdings steadily declined over the next couple of years. As of September 2023, the value of his holdings had dropped to approximately $1.65 million. This fluctuation highlights the volatile nature of biotech stocks and how they are often influenced by company performance and market conditions. Shaw's involvement in these trades shows not only his deep connection to the company's success but also the risks that come with investing in high-growth industries.

Total Stock Sold

$1.45M

CDXS

$1.45M

181,666 CDXS shares

What if they kept their stock?

If Alan Shaw didn't sell their stock, today they would have:
Extra CDXS181,666 shares worth $1.95M.
This is 34.89% and $505.56K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Alan Shaw.

CDXS

$283.98K

CDXS at $5.27/share

Dec 15, 2011

Sale

CDXS

$200.27K

CDXS at $5.30/share

Dec 13, 2011

Sale

CDXS

$151.07K

CDXS at $10.07/share

Jul 6, 2011

Sale

CDXS

$155.89K

CDXS at $10.39/share

Jun 1, 2011

Sale

CDXS

$156.66K

CDXS at $10.44/share

May 2, 2011

Sale

CDXS

$181.02K

CDXS at $12.07/share

Apr 1, 2011

Sale

CDXS

$159.74K

CDXS at $10.65/share

Mar 1, 2011

Sale

CDXS

$156.90K

CDXS at $10.46/share

Feb 11, 2011

Sale

CDXS

75,000 shares

CDXS

Jan 26, 2011

Received

Compensation History

See how much did Alan Shaw make over time.

Alan Shaw’s compensation during his leadership at Codexis varied significantly from year to year, reflecting both his effectiveness as a CEO and the company’s performance. In 2017, for instance, he earned a total of $3.37 million, which included a base salary of $627,500 and a performance-based bonus of $473,000. His bonus structure was tied to achieving specific corporate goals, demonstrating his focus on aligning his pay with company success. In previous years, he had seen total compensation dip as low as $1.25 million in 2015, showcasing the ups and downs tied to the company's performance. This compensation strategy aimed to attract and retain top talent while motivating executives to drive company success and shareholder value.

Year

2017

Total Compensation

$2.61M

Salary

$627.50K

Board Justification

The compensation philosophy is designed to attract, retain, and motivate top talent, aligning executive compensation with company performance and shareholder interests.

Bonus

$473.00K

Board Justification

The bonus for 2017 was based on a combination of corporate performance metrics and individual performance factors, resulting in an overall achievement factor of 91.7%.

Other

$12.04K

Board Justification

Other compensation includes a cell phone stipend and 401(k) matching contributions.

Restricted Stock

$1.50M(360.52K RSU)

Board Justification

The stock awards that vested in 2017 were based on performance stock units (PSUs) that were achieved at a level of 134.2% of target, with shares vesting upon achievement and continued employment.

Performance Metrics

Performance metrics included revenue growth, non-GAAP income growth, fundraising, and strategic advancements in biotherapeutics.

Other Codexis CEOs

Here are other CEOs of Codexis

John Nicols

Ex-CEO of Codexis

November 2017 - September 2022